GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback